Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Arlo Technologies, Inc. (ARLO), Micron Technology, Inc. (MU) & Ferroglobe PLC (GSM): Bronstein, Gewirtz & Grossman, LLC Class Action Update

ARLO, MU, GSM

NEW YORK, NY / ACCESSWIRE / February 22, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed againstthe following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Arlo Technologies, Inc. (NYSE: ARLO)

Class Period: common stock purchased pursuant and/or traceable to Arlo's August 3, 2018 initial public offering (the ''IPO'' or the ''Offering'').
Lead Plaintiff Deadline: March 25, 2019
For more info: www.bgandg.com/arlo

The Complaint alleges that Defendants made materially false and misleading statementsand/or failed to disclose that: (1) there was a flaw and/or quality issue with Arlo's newly designed battery for its Ultra camera systems; (2) this flaw and/or quality issue with the Ultra battery could result in a shipping delay of Arlo's Ultra product; (3) such a shipping delay endangered Arlo's chances of launching the Ultra product in time for the crucial holiday season; (4) such a shipping delay would allow Arlo's competitors to capitalize on the Ultra product's missed launch, thereby increasing their own market share; (5) Arlo's consumers had been experiencing battery drain issues and other battery-related issues in connection with recent firmware updates; (6) because of the foregoing, Arlo's fourth quarter 2018 results and consumer base would be negatively impacted; and (7) as a result, Arlo's Registration Statement was materially false and misleading at all relevant times.

Micron Technology, Inc.(NASDAQ: MU)

Class Period: September 26, 2017 - November 19, 2018
Lead Plaintiff Deadline: March 25, 2019
For more info: www.bgandg.com/mu

The Complaint alleges that throughout the Class Period Defendants made materially false and misleading statementsand/or failed to disclose that Micron was engaged in a price-fixing conspiracy with Samsung Electronics and SK Hynix, and that such unlawful behavior could lead to severe sanctions against the Company.

Ferroglobe PLC (NASDAQ: GSM)

Class Period: August 21, 2018 - November 26, 2018
Lead Plaintiff Deadline: March 25, 2019
For more info: www.bgandg.com/gsm

The Complaint alleges that throughout the Class Period Defendants made materially false and misleading statementsand/or failed to disclose that: (1) that there was excess supply of the Company's products; (2) that demand for the Company's products was declining; (3) that, as a result, the pricing of the Company's products would be materially impacted; and (4) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

Tyme Technologies, Inc. (NASDAQ: TYME)

Class Period: March 14, 2018 - January 18, 2019
Lead Plaintiff Deadline: March 29, 2019
For more info: www.bgandg.com/tyme

The Complaint alleges that Defendants made materially false and misleading statementsand/or failed to disclose that: (1) Tyme had not adequately designed the Phase II Study to present reliable results on the efficacy of SM-88 on pancreatic cancer; (2) Tyme had failed to include an appropriate control group in its open-label Phase II clinical trial for SM-88; (3) the omission of an appropriate control group distorted the reliability of data showing the efficacy of SM-88 in the Phase II Study; and (4) as a result, Tyme's public statements were materially false and misleading at all relevant times.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today